Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 7:18 PM
Ignite Modification Date: 2025-12-25 @ 4:57 PM
NCT ID: NCT04079803
Description: None
Frequency Threshold: 4
Time Frame: 28 days
Study: NCT04079803
Study Brief: PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Placebo Cohort Subjects administered placebo tablets twice daily (BID) for 28 days. 0 None 0 22 12 22 View
Simufilam (PTI-125), 100 mg Tablets Cohort Subjects administered simufilam 100 mg tablets twice daily (BID) for 28 days. 0 None 0 21 9 21 View
Simufilam (PTI-125), 50 mg Tablets Cohort Subjects administered simufilam 50 mg tablets twice daily (BID) for 28 days. 0 None 0 21 4 21 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Fatigue SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders Medra View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders Medra View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders Medra View
Any adverse event SYSTEMATIC_ASSESSMENT General disorders Medra View